The name packs three ideas together: the parent molecule, plus two specific engineering changes.

IGF-1 is Insulin-like Growth Factor 1, a growth factor made mainly by the liver that mediates many of growth hormone’s effects. LR3 describes how this version differs: L for “Long,” meaning a 13-amino-acid extension added to the front (N-terminus), and R3 meaning an arginine substituted at position 3 in place of the natural residue. So “IGF-1 LR3” reads as Long-Arg3 IGF-1.

It is a single-chain recombinant protein — longer and heavier than natural IGF-1 — folded with internal disulfide bonds.

At 83 residues the sequence is too long to list usefully here, so it is described rather than printed. Two changes define it against natural IGF-1: the arginine substitution at position 3 (replacing the natural glutamate), and the added 13-amino-acid segment at the front of the chain. The three disulfide bonds must form correctly for the protein to fold and function.

Its parent, IGF-1, has a long research history; the LR3 version is a much later laboratory tool.

The activity now attributed to IGF-1 was first noticed in the 1950s as a “sulfation factor” or somatomedin (Salmon and Daughaday, 1957), and the protein’s primary structure was determined by Rinderknecht and Humbel in 1978. The Long-Arg3 analog was developed later, in the 1990s, as a more potent reagent for cell-culture research — work associated with the Australian group GroPep — not as a human medicine.

The goal was to free IGF-1 from the proteins that normally hold it inactive, making it far more potent in a dish.

In the body, most IGF-1 is bound to a family of IGF binding proteins (IGFBPs) that limit how much is free to act. The arginine-at-position-3 substitution sharply lowers the analog’s affinity for those binding proteins, and the N-terminal extension further stabilizes the molecule. Together these changes leave much more of the growth factor available to its receptor, which is exactly what makes it a strong stimulus in cell culture.

Unlike the short peptides on this site, IGF-1 LR3 is too large for simple chemical synthesis and is made recombinantly.

A gene encoding the 83-amino-acid sequence is expressed in engineered host cells, commonly E. coli. The protein is then recovered, refolded so that its three disulfide bonds pair correctly, and purified by chromatography. Because misfolding is a real risk with disulfide-containing proteins, quality control confirms both the correct mass (by mass spectrometry) and proper folding.

This is essential context: IGF-1 LR3 was designed and validated as a cell-culture reagent, not as a treatment.

Its documented strength is exactly that role — it reliably drives cell growth and survival in laboratory culture, which is why suppliers list it for research use. There are essentially no human clinical trials of IGF-1 LR3 establishing safety or benefit in people, and its exaggerated potency relative to natural IGF-1 is a laboratory feature, not evidence of a therapeutic profile. Claims about human effects are not supported by the kind of controlled clinical data that would back an approved medicine.

This entry is a research and educational reference only. It is not a drug or supplement, and it provides no dosing, timing, or usage guidance.